BR112022019168A2 - Tratamento de distúrbios respiratórios - Google Patents

Tratamento de distúrbios respiratórios

Info

Publication number
BR112022019168A2
BR112022019168A2 BR112022019168A BR112022019168A BR112022019168A2 BR 112022019168 A2 BR112022019168 A2 BR 112022019168A2 BR 112022019168 A BR112022019168 A BR 112022019168A BR 112022019168 A BR112022019168 A BR 112022019168A BR 112022019168 A2 BR112022019168 A2 BR 112022019168A2
Authority
BR
Brazil
Prior art keywords
treatment
breathing disorders
disorders
breathing
compounds
Prior art date
Application number
BR112022019168A
Other languages
English (en)
Inventor
Fenaux Martijn
T Jones Christopher
K Quirk Erin
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of BR112022019168A2 publication Critical patent/BR112022019168A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO DE DISTÚRBIOS RESPIRATÓRIOS. A presente invenção refere-se a compostos para uso no tratamento de distúrbios respiratórios.
BR112022019168A 2020-03-25 2021-03-25 Tratamento de distúrbios respiratórios BR112022019168A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994617P 2020-03-25 2020-03-25
PCT/US2021/024239 WO2021195435A1 (en) 2020-03-25 2021-03-25 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
BR112022019168A2 true BR112022019168A2 (pt) 2022-11-01

Family

ID=77892404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019168A BR112022019168A2 (pt) 2020-03-25 2021-03-25 Tratamento de distúrbios respiratórios

Country Status (13)

Country Link
US (1) US20230127498A1 (pt)
EP (1) EP4125968A4 (pt)
JP (1) JP2023529255A (pt)
KR (1) KR20220158022A (pt)
CN (1) CN115666577A (pt)
AU (1) AU2021241646A1 (pt)
BR (1) BR112022019168A2 (pt)
CA (1) CA3176881A1 (pt)
CL (1) CL2022002589A1 (pt)
IL (1) IL296816A (pt)
MX (1) MX2022011888A (pt)
PE (1) PE20230997A1 (pt)
WO (1) WO2021195435A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149957A (zh) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
HUE038437T2 (hu) * 2012-05-02 2018-10-29 Boehringer Ingelheim Int Az SSAO szubsztituált 3-halogén-allil-amin inhibitorai és ezek alkalmazásai
GB201304527D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201513115D0 (en) * 2015-07-24 2015-09-09 Proximagen Ltd New therapeutic compound and use in therapy
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
KR20190070956A (ko) * 2016-10-19 2019-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
CN110352188B (zh) * 2017-04-28 2022-11-29 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
CN109988109B (zh) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用

Also Published As

Publication number Publication date
WO2021195435A1 (en) 2021-09-30
EP4125968A4 (en) 2024-04-10
PE20230997A1 (es) 2023-06-26
AU2021241646A1 (en) 2022-11-24
JP2023529255A (ja) 2023-07-10
US20230127498A1 (en) 2023-04-27
CL2022002589A1 (es) 2023-03-31
CN115666577A (zh) 2023-01-31
MX2022011888A (es) 2023-03-06
KR20220158022A (ko) 2022-11-29
CA3176881A1 (en) 2021-09-30
IL296816A (en) 2022-11-01
EP4125968A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112015020941A2 (pt) uso de derivados de pirazolopirimidina para o tratamento de distúrbios relacionados a pi3kdelta
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112013033417A2 (pt) compostos terapêuticos e métodos relacionados de uso
MX2021003905A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
NI201600021A (es) Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CL2019001727A1 (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.
BR112022019168A2 (pt) Tratamento de distúrbios respiratórios
CL2019001726A1 (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios.
BR112013004721A2 (pt) "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3"
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CL2021001359A1 (es) Proceso para la producción de formas farmacéuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios
BR112018002763A2 (pt) método para cicatrização de ferimentos
BR112016029624A2 (pt) terapia usando um inibidor do fator xii em um distúrbio neurotraumático
BR112023025789A2 (pt) Nitroxolina para uso no tratamento de neurofibroma cutâneo
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais
BR112012029815A2 (pt) derivados de flufenoxina pra o tratamento e prevenção de patologias amiloides
PL428024A1 (pl) Sulfonowana pochodna polistyrenu do zastosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez kociego herpeswirusa

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing